Cerebrospinal fluid α‐synuclein contributes to the differential diagnosis of Alzheimer's disease

Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach

DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649 · see citing works

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · see citing works

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · see citing works

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · see citing works

Classification of primary progressive aphasia and its variants

Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · see citing works

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium

McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works

The Determinants of Quality of Life of Nursing Home Residents with Young-Onset Dementia and the Differences between Dementia Subtypes

Appelhof, B., Bakker, C., den IJssel, J. C. L. V. D., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,773 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia

van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., Swieten, J. C. V., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,061 · see citing works

Mixed brain pathologies account for most dementia cases in community-dwelling older persons

Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · see citing works

α-Synuclein is phosphorylated in synucleinopathy lesions

Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 1,906 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease

HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works

Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease

Anderson, J. P., Walker, D., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,418 · see citing works

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales

(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338 · see citing works

Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force

Dubois, B., Burn, D. J., Goetz, C. G., Aarsland, D., Brown, R. G., Broe, G. A., Dickson, D. W., Duyckaerts, C. J., Cummings, J., Gauthier, S. G., et al. (2007) · Movement Disorders · doi:10.1002/mds.21844 · Cited by 1,069 · see citing works

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update

Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · see citing works

Receiver Operating Characteristic Curves and Their Use in Radiology

Obuchowski, N. A. (2003) · Radiology · doi:10.1148/radiol.2291010898 · Cited by 843 · see citing works

Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

Hamilton, R. L. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00269.x · Cited by 754 · see citing works

Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease

Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676 · see citing works

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615 · see citing works

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

Irwin, D. J., Grossman, M., Weintraub, D. A., Hurtig, H. I., Duda, J. E., Xie, S. X., Lee, E. B., Deerlin, V. M. V., López, O. L., Kofler, J., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30291-5 · Cited by 588 · see citing works

Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes

Lippa, C. F., Fujiwara, H., Mann, D. M. A., Giasson, B., Baba, M., Schmidt, M. L., Nee, L. E., O'Connell, B., Pollen, D. A., St. George-Hyslop, P., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65722-7 · Cited by 533 · see citing works

Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders

Litvan, I., Hauw, J., Bartko, J. J., Lantos, P. L., Daniel, S. E., Horoupian, D. S., McKee, A. C., Dickson, D. W., Bancher, C., Tabaton, M., et al. (1996) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199601000-00010 · Cited by 474 · see citing works

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., Nilsson, C., Widner, H., Decraemer, H., Nägga, K., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1654 · Cited by 473 · see citing works

Imaging amyloid deposition in Lewy body diseases

Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443 · see citing works

Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease: A Comparative Cerebrospinal Fluid Study

Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works

Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology

Olsson, A., Vanderstichele, H., Andreasen, N., Meyer, G. D., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 424 · see citing works

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Shi, M. Y., Bradner, J. M., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J. J., Zabetian, C. P., Kim, H. M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22311 · Cited by 418 · see citing works

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

Schoonenboom, N. S. M., Reesink, F. E., Verwey, N. A., Kester, M. I., Teunissen, C. E., van de Ven, P. M., Pijnenburg, Y. A. L., Blankenstein, M. A., Rozemuller, A. J., Scheltens, P., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31823ed0f0 · Cited by 302 · see citing works

Phosphorylated α-Synuclein in Parkinson’s Disease

Wang, Y., Shi, M. Y., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. ‐., Siderowf, A. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002566 · Cited by 281 · see citing works

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

Majbour, N. K., Vaikath, N. N., van Dijk, K. D., Ardah, M. T., Varghese, S., Vesterager, L. B., Montezinho, L. P., Poole, S., Safieh‐Garabedian, B., Tokuda, T., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0072-9 · Cited by 279 · see citing works

A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank

Toledo, J. B., Van Deerlin, V. M., Lee, E. B., Suh, E., Baek, Y., Robinson, J. L., Xie, S. X., McBride, J., Wood, E. M., Schuck, T., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.06.003 · Cited by 234 · see citing works

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease

Grossman, M., Farmer, J., Leight, S., Work, M., Moore, P., Van Deerlin, V., Pratico, D., Clark, C. M., Coslett, H. B., Chatterjee, A., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20477 · Cited by 228 · see citing works

CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease

Shi, M., Kovac, A., Korff, A., Cook, T. J., Ginghina, C., Bullock, K. M., Yang, L., Stewart, T., Zheng, D., Aro, P., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.003 · Cited by 206 · see citing works

CSF biomarkers cutoffs: The importance of coincident neuropathological diseases

Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · see citing works

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Mattsson, N., Lönneborg, A., Boccardi, M., Blennow, K., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.034 · Cited by 134 · see citing works

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large‐scale international multicenter study

Ewers, M., Mattsson, N., Minthon, L., Molinuevo, J. L., Antonell, A., Popp, J., Jessen, F., Herukka, S., Soininen, H., Maetzler, W., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.006 · Cited by 133 · see citing works

Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies

Gómez‐Isla, T., Growdon, W., McNamara, M. J., Newell, K. L., Gómez‐Tortosa, E., Hedley‐Whyte, E. T., & Hyman, B. T. (1999) · Neurology · doi:10.1212/wnl.53.9.2003 · Cited by 122 · see citing works

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106 · see citing works

Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis

Struyfs, H., Broeck, B. V., Timmers, M., Fransén, E., Sleegers, K., Broeckhoven, C. V., Deyn, P. P. D., Streffer, J. R., Mercken, M. H., & Engelborghs, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141986 · Cited by 104 · see citing works

Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis

Möller, C., Pijnenburg, Y. A. L., van der Flier, W. M., Versteeg, A., Tijms, B., de Munck, J. C., Hafkemeijer, A., Rombouts, S. A. R. B., van der Grond, J., van Swieten, J., et al. (2016) · Radiology · doi:10.1148/radiol.2015150220 · Cited by 103 · see citing works

α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works

Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia

Grossman, M., Libon, D. J., Forman, M. S., Massimo, L. M., Wood, E. M., Moore, P., Anderson, C., Farmer, J. M., Chatterjee, A. K., Clark, C. M., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1601 · Cited by 94 · see citing works

Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias

Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H., Wolf, S., Trenkwalder, C., Otto, M., Stiens, G., Rüther, E., Kornhuber, J., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001967 · Cited by 90 · see citing works

Multiparametric computer-aided differential diagnosis of Alzheimer’s disease and frontotemporal dementia using structural and advanced MRI.

Bron, E. E., Smits, M., Papma, J. M., Steketee, R. M. E., Meijboom, R., de Groot, M., van Swieten, J. C., Niessen, W. J., & Klein, S. (2017) · European Radiology · doi:10.1007/s00330-016-4691-x · Cited by 84 · see citing works

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events

Blennow, K., & Zetterberg, H. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00345 · Cited by 77 · see citing works

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease

Majbour, N. K., Chiasserini, D., Vaikath, N. N., Eusebi, P., Tokuda, T., van de Berg, W., Parnetti, L., Calabresi, P., & El-Agnaf, O. M. A. (2017) · Scientific Reports · doi:10.1038/srep40263 · Cited by 55 · see citing works

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

Struyfs, H., Niemantsverdriet, E., Goossens, J., Fransén, E., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00138 · Cited by 52 · see citing works

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia

Akhtar, R. S., Xie, S. X., Chen, Y. J., Rick, J. H., Gross, R. G., Nasrallah, I. M., Deerlin, V. M. V., Trojanowski, J. Q., Chen‐Plotkin, A. S., Hurtig, H. I., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177924 · Cited by 47 · see citing works

Pathologic Correlates of Dementia in Individuals with Lewy Body Disease

Sonnen, J. A., Postupna, N. O., Larson, E. B., Crane, P. K., Rose, S. E., Montine, K. S., Leverenz, J. B., & Montine, T. J. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00371.x · Cited by 42 · see citing works

Multiple pathologies are common in Alzheimer patients in clinical trials

Wang, B. W., Lu, E., Mackenzie, I. R. A., Assaly, M., Jacova, C., Lee, P. E., Beattie, B. L., & Hsiung, G. Y. R. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015316 · Cited by 41 · see citing works

Rate of Decline in Alzheimer Disease Measured by a Dementia Severity Rating Scale

Xie, S. X., Ewbank, D. C., Chittams, J. L., Karlawish, J. H., Arnold, S. E., & Clark, C. M. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318194a324 · Cited by 41 · see citing works

Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

Tang, W. X., Huang, Q., Yao, Y., Wang, Y., Wu, Y., & Wang, Z.-Y. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1226-y · Cited by 31 · see citing works

Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease

XIE, S. X., LIBON, D. J., WANG, X., MASSIMO, L., MOORE, P., VESELY, L., KHAN, A., CHATTERJEE, A., COSLETT, H. B., HURTIG, H. I., et al. (2010) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617709991317 · Cited by 27 · see citing works

Increased CSF E-Selectin in Clinical Alzheimer’s Disease without Altered CSF A β 42 and Tau

Li, G., Xiong, K., Korff, A., Pan, C., Quinn, J. F., Galasko, D. R., Liu, C., Montine, T. J., Peskind, E. R., & Zhang, J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150420 · Cited by 20 · see citing works

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

α-synuclein in the pathophysiology of Alzheimer’s disease

Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders

Irwin, D. J., & Hurtig, H. I. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000444 · Cited by 165 · see citing works

Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 149 · see citing works

An outline for the pharmacological effect of icariin in the nervous system

Jin, J., Wang, H., Hua, X., Chen, D., Huang, C., & Chen, Z. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.006 · Cited by 137 · see citing works

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

Irwin, D. J., Fedler, J. K., Coffey, C. S., Caspell‐Garcia, C., Kang, J., Simuni, T., Foroud, T., Toga, A. W., Tanner, C. M., Kieburtz, K. D., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25811 · Cited by 108 · see citing works

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies

van Steenoven, I., Majbour, N. K., Vaikath, N. N., Berendse, H. W., van der Flier, W. M., van de Berg, W. D. J., Teunissen, C. E., Lemstra, A. W., & El‐Agnaf, O. M. A. (2018) · Movement Disorders · doi:10.1002/mds.111 · Cited by 103 · see citing works

Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease

Shim, K. H., Kang, M. J., Youn, Y. C., An, S. S. A., & Kim, S. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01150-0 · Cited by 98 · see citing works

The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death

Thal, D. R., & Tomé, S. O. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.10.006 · Cited by 85 · see citing works

Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases

Seino, Y., Nakamura, T., Kawarabayashi, T., Hirohata, M., Narita, S., Wakasaya, Y., Kaito, K., Ueda, T., Harigaya, Y., & Shoji, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181152 · Cited by 49 · see citing works

Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study

Han, Z., Tian, R., Ren, P., Zhou, W., Wang, P., Luo, M., Jin, S., & Jiang, Q. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0721-7 · Cited by 46 · see citing works

Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting

Kokkinou, M., Beishon, L., Smailagic, N., Noel-Storr, A. H., Hyde, C., Ukoumunne, O. C., Worrall, R., Hayen, A., Desai, M., Ashok, A. H., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010945.pub2 · Cited by 42 · see citing works

Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying α-Synuclein–Containing Extracellular Vesicles

Hong, Z., Tian, C., Stewart, T., Aro, P., Soltys, D., Bercow, M., Sheng, L., Borden, K., Khrisat, T., Pan, C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011853 · Cited by 35 · see citing works

The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology

Førland, M. G. G., Tysnes, O., Aarsland, D., Maple‐Grødem, J., Pedersen, K. F., Alves, G. W., & Lange, J. (2019) · European Journal of Neurology · doi:10.1111/ene.14032 · Cited by 33 · see citing works

A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance

Kumar, D., Sharma, A., & Sharma, L. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200203101828 · Cited by 33 · see citing works

Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage

Bousiges, O., Philippi, N., Lavaux, T., Perret‐Liaudet, A., Lachmann, I., Schaeffer‐Agalède, C., Anthony, P., Botzung, A., Rauch, L., Jung, B., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00684-5 · Cited by 31 · see citing works

Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline

Nair, A. K., Hulle, C. A. V., Bendlin, B. B., Zetterberg, H., Blennow, K., Wild, N., Kollmorgen, G., Suridjan, I., Busse, W. W., & Rosenkranz, M. A. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12315 · Cited by 30 · see citing works

CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation

Shim, K. H., Kang, M. J., Suh, J. W., Pyun, J., Ryoo, N., Park, Y. H., Youn, Y. C., Jang, J., Jeong, J. H., Park, K. W., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00648-9 · Cited by 26 · see citing works

High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse

Piccarducci, R., Pietrobono, D., Pellegrini, C., Daniele, S., Fornai, M., Antonioli, L., Trincavelli, M. L., Blandizzi, C., & Martini, C. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5030475 · Cited by 26 · see citing works

Alpha-synuclein Levels in the Differential Diagnosis of Lewy Bodies Dementia and Other Neurodegenerative Disorders

Mavroudis, I. A., Petridis, F., Chatzikonstantinou, S., & Kazis, D. A. (2020) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000381 · Cited by 22 · see citing works

Detection and assessment of alpha-synuclein in Parkinson disease

Tsao, H.-H., Huang, C., & Wu, Y. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105358 · Cited by 22 · see citing works

Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer’s Disease and Other Proteinopathies

Kotarba, S., Kozłowska, M., Scios, M., Saramowicz, K., Barczuk, J., Granek, Z., Siwecka, N., Wiese, W., Golberg, M., Galita, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910797 · Cited by 21 · see citing works

Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice

Shaw, L. M. J., Korecka, M., Figurski, M., Toledo, J. B., Irwin, D. J., Kang, J., & Trojanowski, J. Q. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029587 · Cited by 21 · see citing works

Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease

García‐Ayllón, M., Monge-Argilés, J. A., Monge‐García, V., Navarrete, F., Cortés‐Gómez, M., Sánchez–Payá, J., Manzanares, J., Gasparini‐Berenguer, R., Leiva-Santana, C., & Sáez‐Valero, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14719 · Cited by 17 · see citing works

Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia

Álvarez, I., Díez-Fairén, M., Aguilar, M., González, J. M., Ysamat, M., Tartari, J. P., Cárcel, M., Alonso, Á., Brix, B., Arendt, P., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14658 · Cited by 17 · see citing works

CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort

Lei, D., Mao, C., Li, J., Huang, X., Sha, L., Liu, C., Dong, L., Xu, Q., & Gao, J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1030019 · Cited by 14 · see citing works

Cerebrospinal Fluid, Imaging, and Physiological Biomarkers in Dementia With Lewy Bodies

Mavroudis, I. A., Petridis, F. E., & Kazis, D. (2019) · American Journal of Alzheimers Disease & Other Dementias · doi:10.1177/1533317519869700 · Cited by 10 · see citing works

α-synuclein as an emerging pathophysiological biomarker of Alzheimer’s disease

Beatino, M. F., Luca, C. D., Campese, N., Belli, E., Piccarducci, R., Giampietri, L., Martini, C., Perugi, G., Siciliano, G., Ceravolo, R., et al. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2068952 · Cited by 11 · see citing works

Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: an update of the literature

Milos, T., Vuić, B., Balic, N., Farkaš, V., Erjavec, G. N., Štrac, D. Š., Perković, M. N., & Pivac, N. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2400683 · Cited by 11 · see citing works

Luminex-based quantification of Alzheimer's disease neuropathologic change in formalin-fixed post-mortem human brain tissue

Keene, C. D., Wilson, A. M., Kilgore, M. D., Bruner, L. T., Postupna, N. O., & Darvas, M. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0165-x · Cited by 11 · see citing works

The Association Between Plasma α-Synuclein (α-syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE ε4) Alleles and Cognitive Decline in 60 Patients with Alzheimer’s Disease Compared with 28 Age-Matched Normal Individuals

Lv, S., Zhou, X., Li, Y., Zhang, S., Wang, Y., Jia, S., Niu, X., Wang, L., & Peng, D. (2021) · Medical Science Monitor · doi:10.12659/msm.932998 · Cited by 9 · see citing works

Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease

Monge‐García, V., García‐Ayllón, M., Sáez‐Valero, J., Sánchez–Payá, J., Navarrete, F., Manzanares, J., Gasparini‐Berenguer, R., Romero‐Lorenzo, R., Cortés‐Gómez, M., & Monge-Argilés, J. A. (2021) · Medicina · doi:10.3390/medicina57090954 · Cited by 9 · see citing works

Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion

Ding, Y., Wang, L., Liu, J., Deng, Y., Jiao, Y., & Zhao, A. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100040 · Cited by 8 · see citing works

Beyond amyloid plaque, targeting α-synuclein in Alzheimer disease: The battle continues

Al-Kuraishy, H. M., Sulaiman, G. M., Mohammed, H. A., Al-Gareeb, A. I., Albuhadily, A. K., Ali, A. A., & Abu-Alghayth, M. H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102684 · Cited by 10 · see citing works

A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia

Lucena, D. D., Escaramís, G., Villar‐Piqué, A., Hermann, P., Schmitz, M., Varges, D., Santana, I. J., del Rı́o, J. A., Martı́, E., Ferrer, I., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09870-9 · Cited by 8 · see citing works

PET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use

Juengling, F. D., Wuest, F. R., Schirrmacher, R., Abele, J. T., Thiel, A., Soucy, J., Camicioli, R. M., & Garibotto, V. (2024) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2024.31 · Cited by 5 · see citing works

Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease

Monge-García, S., García‐Ayllón, M., Sánchez–Payá, J., Gasparini‐Berenguer, R., Cortés‐Gómez, M., Sáez‐Valero, J., & Monge-Argilés, J. A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1124145 · Cited by 4 · see citing works

A Survey of Cerebrospinal Fluid Total Protein Upper Limits in Canada: Time for an Update?

Bourque, P. R., McCudden, C. R., Warman‐Chardon, J., Brooks, J., Hegen, H., Deisenhammer, F., & Breiner, A. (2019) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2019.12 · Cited by 4 · see citing works

Neuropathological Validation of Cerebrospinal Fluid Biomarkers in Neurodegenerative Diseases

Irwin, D. J. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029876 · Cited by 2 · see citing works

Salivary biomarkers for the molecular diagnosis of dementia with Lewy bodies

D’Antonio, F., Vivacqua, G., Serrentino, M., Nalepa, M., Skweres, A., Peconi, M., Bartolo, M. I. D., Panigutti, M., Monti, M. S., Talarico, G., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251317720 · Cited by 1 · see citing works

Alzheimer's disease therapeutics

Sang, Z., & Huang, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00031-0 · Cited by 1 · see citing works

Linking Parkinson’s disease and Alzheimer’s disease: A Mendelian Randomization Study on Causal Relationships and Clinical ImplicationsPreprint

Kuruvilla, J., Yong, Y. T., Lee, W. J., Yap, K., Deng, X., Tan, E., & Xiao, B. (2025) · Research Square · doi:10.21203/rs.3.rs-5954887/v1

Elevated CSF Serotonin in Prodromal Alzheimer’s Disease Patients Developing Psychosis

Monge‐García, V., Pérez‐González, R., Monge-García, S., Gasparini‐Berenguer, R., Sánchez–Payá, J., Silva-Afonso, R. D. F., & Monge-Argilés, J. A. (2026) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad3010014

Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels

Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85 · see citing works

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106 · see citing works

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies

van Steenoven, I., Majbour, N. K., Vaikath, N. N., Berendse, H. W., van der Flier, W. M., van de Berg, W. D. J., Teunissen, C. E., Lemstra, A. W., & El‐Agnaf, O. M. A. (2018) · Movement Disorders · doi:10.1002/mds.111 · Cited by 103 · see citing works

CSF α-Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease

Reesink, F. E., Lemstra, A. W., van Dijk, K. D., Berendse, H. W., van de Berg, W. D. J., Klein, M., Blankenstein, M. A., Scheltens, P., Verbeek, M. M., & van der Flier, W. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100186 · Cited by 84 · see citing works

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Chiasserini, D., Biscetti, L., Eusebi, P., Salvadori, N., Frattini, G., Simoni, S., Roeck, N. D., Tambasco, N., Stoops, E., Vanderstichele, H., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0276-4 · Cited by 138 · see citing works